University of Mississippi, Oxford

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Mississippi, Oxford sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 9 completed early-phase tilt top decile by trial count

University of Mississippi, Oxford: 10 sponsored US clinical trials, 1 recruiting.

University of Mississippi, Oxford sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is G6PD Deficiency, with 1 trials.

Top-decile sponsor footprint

University of Mississippi, Oxford ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING NA

Time-restricted Eating Acceptability, Efficacy and Safety in Obesity

NCT06695988
COMPLETED NA

Vascular Adaptations to Single-Sprint Training

NCT05727332
COMPLETED NA

Effects of Early Time Restricted Eating on Muscle Performance in Resistance Trained Individuals

NCT05908201
COMPLETED Early Phase 1

CBD Cannabis Extract: Pharmacokinetic Studies

NCT04280289
COMPLETED NA

Online Education Intervention to Reduce Ageism Among Undergraduate Students

NCT04570917
COMPLETED Phase 1

Primaquine Enantiomers in G6PD Deficient Human Volunteers

NCT04073953
COMPLETED Phase 1

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

NCT03934450
COMPLETED Phase 1

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1

NCT02898779
COMPLETED NA

Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD

NCT01773811
COMPLETED NA

Method of Fish Oil Administration on Patient Compliance

NCT01471366

Phase Distribution

PhaseTrial count
Phase 1 4

Therapeutic Areas

G6PD Deficiency 1
Cardiovascular System 1
Time-restricted Eating 1

What is open in the University of Mississippi, Oxford pipeline

1 recruiting of 10 indexed (10% open); 9 completed (90%).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: G6PD Deficiency (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Mississippi, Oxford: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of Mississippi, Oxford sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share University of Mississippi, OxfordAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
University of Mississippi, Oxford sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Mississippi, Oxford sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Mississippi, Oxford page

10 registered trials is a research-attention snapshot, not an endorsement of University of Mississippi, Oxford or any single study.

  • 1 of University of Mississippi, Oxford's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • G6PD Deficiency is the condition University of Mississippi, Oxford studies most, compare against other sponsors active in the same condition before evaluating a specific study. See G6PD Deficiency trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Mississippi, Oxford pipeline card: 10 registered trials from official public datasets.Report a data error.